Heeb M J, España F, Gittes R F, Griffin J H
Scripps Research Institute, La Jolla, CA 92037, USA.
Biochem Mol Biol Int. 1995 Nov;37(5):917-23.
Quantitative immunoblotting of prostate cancer patient sera revealed that most prostate specific antigen was in complexes with alpha 1-antichymotrypsin or alpha 2-macroglobulin with little of it being free antigen. Complexes of prostate specific antigen with these protease inhibitors in patient sera comigrated during electrophoresis with the respective purified complexes. Each complex was selectively removed from patient sera by absorption with specific antibodies. When prostate specific antigen was added to normal plasma, complexes with alpha 2-macroglobulin appeared first and after 1 hr, the distribution was approximately 40% free antigen, approximately 40% complexes with alpha 2-macroglobulin, and approximately 20% complexes with alpha 1-antichymotrypsin. These data show that prostate specific antigen reacts more readily with alpha 2-macroglobulin than with any other protease inhibitor in plasma and that the antigen complexes with alpha 2-macroglobulin in vivo in cancer patients.
对前列腺癌患者血清进行定量免疫印迹分析发现,大多数前列腺特异性抗原与α1 -抗糜蛋白酶或α2 -巨球蛋白形成复合物,只有少量为游离抗原。患者血清中前列腺特异性抗原与这些蛋白酶抑制剂形成的复合物在电泳过程中与各自的纯化复合物共迁移。通过用特异性抗体吸附,可从患者血清中选择性去除每种复合物。当将前列腺特异性抗原添加到正常血浆中时,与α2 -巨球蛋白形成的复合物首先出现,1小时后,其分布约为40%游离抗原、约40%与α2 -巨球蛋白形成的复合物和约20%与α1 -抗糜蛋白酶形成的复合物。这些数据表明,前列腺特异性抗原与血浆中α2 -巨球蛋白的反应比与任何其他蛋白酶抑制剂的反应更迅速,并且在癌症患者体内该抗原与α2 -巨球蛋白形成复合物。